Vera Therapeutics, Inc. (VERA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$28.20

From 52W high−48.05%

Volume1.27M

Market cap$2.08B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$28.20

From 52W high

−48.05%

Volume

1.27M

Market cap

$2.08B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.2x

P/E (TTM)

—

RSI (14)

43.0

MomentumView details →

1D Return

+3.73%

YTD Return

−42.77%

SummaryUpdated Jun 1, 2026

Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotechnology company founded in 2016 and headquartered in Brisbane, California. Originally incorporated as Trucode Gene Repair, Inc., the company changed its name to Vera Therapeutics in April 2020 and went public in May 2021. The company focuses on developing and commercializing treatments for patients with serious immunological diseases, with its primary emphasis on rare kidney diseases and viral infections that affect immunocompromised patients.

Ask drillr about Vera Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−98.56%

ROA (TTM)

−75.40%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−57.95%

FCF YoY

−60.37%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−69.45%

EBITDA YoY

−87.07%

MomentumView details →

1D Return

+3.73%

YTD Return

−42.77%

1Y Return

−4.04%

RSI (14)

43.0

vs 50D SMA

−10.05%

vs 200D SMA

−23.27%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

10.92x

Quick Ratio

10.92x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.52

EPS Surprise

3.80%

Beats (12Q)

4/12

Next Q EPS Est

−$1.46

Avg Surprise (4Q)

−3.79%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−401.89M

Op. CF (TTM)

−338.65M

Next earningsNov 4, 2026 →

Latest newsMore news →

Vera Therapeutics announced data from the ORIGIN 3 trial, sending its shares lower after an initial spike.34d ago

Similar companies

Agios Pharmaceuticals, Inc.AGIO Mabpharm Limited02181.HK Pharvaris N.V.PHVS Vericel CorporationVCEL BioCryst Pharmaceuticals, Inc.BCRX SELLAS Life Sciences Group, Inc.SLS Find similar companies →

Latest newsMore news →

Vera Therapeutics announced that the ORIGIN 3 final efficacy analysis of TRUTAKNA (atacicept-vymj) in IgA nephropathy will be featured as a late-breaking oral presentation at the opening plenary session of ASN Kidney Week 2026.18d ago Vera Therapeutics announced data from the ORIGIN 3 trial, sending its shares lower after an initial spike.34d ago Vera Therapeutics announced positive final efficacy results from the Phase 3 ORIGIN 3 trial of its kidney disease drug tortacna in adults with primary IgA nephropathy, meeting all pre-specified endpoints.34d ago